Florida jury grants unanimous defense verdict in favor of Novartis

04/09/14

FL

M.D. Fla. -- United States District Court for the Middle District of Florida

Complex Litigation

On April 9, 2014, after deliberating for less than forty-five minutes, a federal jury in Tampa, Florida returned a unanimous verdict in favor of Novartis Pharmaceuticals Corporation in a 3-week trial involving Aredia® and Zometa®, bisphosphonate medicines used to treat cancer patients suffering from metastases to bone.  Dopson-Troutt v. Novartis Pharm. Corp., No. 8:06-cv-1708-T-24-EAJ (M.D. Fl. April 9, 2013).

Plaintiff Ruth Dopson-Troutt alleged that she developed osteonecrosis of the jaw as a result of receiving Aredia® and Zometa® to prevent skeletal-related events – such as bone fractures – when her breast cancer metastasized to her bones.

The jury rejected plaintiff’s Florida-based failure-to-warn claim by answering “No” to the question “Did Novartis negligently fail to provide an adequate warning of the risks of osteonecrosis of the jaw associated with Aredia and/or Zometa to Ruth Dopson-Troutt’s prescribing physician?”

In the Aredia®/Zometa® litigation, Novartis has won complete defense verdicts in seven prior trials, prevailed in twenty-four appellate judgments, and won dismissal or summary judgment in over 250 additional cases.
 
Novartis is represented in this matter by Firm partners Kirby T. Griffis and Matthew J. Malinowski.

What's
Hot

Bloomberg BNA: Monsanto: Cancer Study Suppression is ‘Scientific Vandalism’

Hollingsworth LLP represents Monsanto in In Re:Roundup Products Liability Litigation in the Northern District of California.